Rapid Micro Biosystems (NASDAQ:RPID) Rating Lowered to “Sell” at Wall Street Zen

Rapid Micro Biosystems (NASDAQ:RPID) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.00.

Rapid Micro Biosystems Price Performance

RPID opened at $2.63 on Friday. The business has a 50 day moving average price of $2.80 and a two-hundred day moving average price of $3.35. The company has a quick ratio of 2.36, a current ratio of 3.31 and a debt-to-equity ratio of 0.57. The company has a market cap of $119.56 million, a PE ratio of -2.46 and a beta of 1.52. Rapid Micro Biosystems has a 52 week low of $2.01 and a 52 week high of $4.94.

Rapid Micro Biosystems (NASDAQ:RPID) last issued its earnings results on Thursday, March 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). The business had revenue of $11.28 million for the quarter, compared to analysts’ expectations of $10.93 million. Rapid Micro Biosystems had a negative return on equity of 95.40% and a negative net margin of 140.30%. As a group, research analysts anticipate that Rapid Micro Biosystems will post -0.89 EPS for the current year.

Insider Buying and Selling

In related news, CEO Robert G. Jr. Spignesi sold 17,922 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $4.11, for a total value of $73,659.42. Following the sale, the chief executive officer owned 1,169,848 shares in the company, valued at $4,808,075.28. This represents a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO John J. Addington Wilson sold 9,603 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $4.32, for a total value of $41,484.96. Following the completion of the sale, the chief operating officer owned 316,762 shares in the company, valued at approximately $1,368,411.84. This represents a 2.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 95,989 shares of company stock worth $385,365 in the last quarter. Company insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On Rapid Micro Biosystems

A number of large investors have recently bought and sold shares of RPID. Hudson Bay Capital Management LP acquired a new stake in Rapid Micro Biosystems during the 3rd quarter valued at $38,000. Fifth Lane Capital LP acquired a new stake in Rapid Micro Biosystems during the 4th quarter valued at $51,000. American Century Companies Inc. grew its holdings in Rapid Micro Biosystems by 46.1% during the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock valued at $58,000 after buying an additional 5,341 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Rapid Micro Biosystems during the 4th quarter valued at $71,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in Rapid Micro Biosystems during the 4th quarter valued at $72,000. Institutional investors and hedge funds own 52.60% of the company’s stock.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.